Volume 20, Issue 5, Pages (May 2012)

Slides:



Advertisements
Similar presentations
Teratoma Formation Leads to Failure of Treatment for Type I Diabetes Using Embryonic Stem Cell-Derived Insulin-Producing Cells  Takahisa Fujikawa, Seh-Hoon.
Advertisements

Arachidonic acid and lipoxinA4 attenuate streptozotocin-induced cytotoxicity to RIN5 F cells in vitro and type 1 and type 2 diabetes mellitus in vivo 
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs  Maria Luisa Jaén, Laia Vilà, Ivet Elias,
Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury  Marisa D. Covington,
Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Molecular Therapy - Methods & Clinical Development
Figure 1 Body weight of control and BPA-treated mothers after delivery
Systemic Administration of Multipotent Mesenchymal Stromal Cells Reverts Hyperglycemia and Prevents Nephropathy in Type 1 Diabetic Mice  Fernando E. Ezquer,
Molecular Therapy - Methods & Clinical Development
In vivo Gene Transfer to Healthy and Diabetic Canine Pancreas
Volume 16, Issue 8, Pages (August 2008)
Endovenous Administration of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells Prevents Renal Failure in Diabetic Mice  Fernando Ezquer, Marcelo.
Volume 22, Issue 8, Pages (August 2014)
Volume 15, Issue 1, Pages (January 2007)
Volume 18, Issue 5, Pages (May 2010)
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Volume 17, Issue 5, Pages (May 2009)
Molecular Therapy - Methods & Clinical Development
Chronic high glucose downregulates mitochondrial calpain 10 and contributes to renal cell death and diabetes-induced renal injury  Marisa D. Covington,
Volume 9, Issue 2, Pages (February 2004)
Molecular Therapy - Nucleic Acids
Volume 24, Issue 12, Pages (December 2016)
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 25, Issue 11, Pages (November 2017)
Volume 134, Issue 3, Pages (March 2008)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 9, Pages (September 2010)
Volume 23, Issue 12, Pages (December 2015)
Volume 21, Issue 12, Pages (December 2013)
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs  Maria Luisa Jaén, Laia Vilà, Ivet Elias,
The Stunned β Cell: A Brief History
Volume 9, Issue 4, Pages (April 2004)
Volume 16, Issue 8, Pages (August 2008)
Volume 15, Issue 6, Pages (June 2007)
Volume 19, Issue 11, Pages (November 2011)
Viable Rat-Mouse Chimeras: Where Do We Go from Here?
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 26, Issue 1, Pages (January 2018)
Volume 21, Issue 4, Pages (April 2013)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 56, Issue 4, Pages (October 1999)
Molecular Therapy - Nucleic Acids
Volume 15, Issue 9, Pages (September 2007)
Kailin Xu, Hong Ma, Thomas J. McCown, Inder M. Verma, Tal Kafri 
Volume 1, Issue 4, Pages (April 2005)
Volume 26, Issue 3, Pages (March 2018)
Volume 6, Issue 1, Pages (July 2002)
J.P O'Rourke, H Hiraragi, K Urban, M Patel, J.C Olsen, B.A Bunnell 
Volume 18, Issue 4, Pages (April 2010)
Volume 14, Issue 1, Pages 5-13 (July 2006)
Volume 14, Issue 4, Pages (October 2011)
Computer-assisted Hydrodynamic Gene Delivery
Zhiyu Wang, Nathaniel W. York, Colin G. Nichols, Maria S. Remedi 
In Vivo Tracking of Mesechymal Stem Cells Using Fluorescent Nanoparticles in an Osteochondral Repair Model  Jong Min Lee, Byung-Soo Kim, Haeshin Lee,
Volume 23, Issue 12, Pages (December 2015)
Volume 18, Issue 2, Pages (February 2010)
Volume 20, Issue 3, Pages (March 2012)
Volume 23, Issue 8, Pages (August 2015)
Volume 18, Issue 12, Pages (December 2010)
Volume 18, Issue 6, Pages (June 2010)
Volume 12, Issue 1, Pages (July 2005)
Joan Goulley, Ulf Dahl, Nathalie Baeza, Yuji Mishina, Helena Edlund 
Molecular Therapy - Nucleic Acids
Volume 18, Issue 7, Pages (July 2010)
Volume 17, Issue 5, Pages (May 2009)
Systemic Administration of Platelets Incorporating Inactivated Sendai Virus Eradicates Melanoma in Mice  Tomoyuki Nishikawa, Li Yu Tung, Yasufumi Kaneda 
Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice  Jun Yoshino, Kathryn F. Mills,
Zhiyu Wang, Nathaniel W. York, Colin G. Nichols, Maria S. Remedi 
Presentation transcript:

Volume 20, Issue 5, Pages 918-926 (May 2012) Reversal of Diabetes Through Gene Therapy of Diabetic Rats by Hepatic Insulin Expression via Lentiviral Transduction  Matthias Elsner, Taivankhuu Terbish, Anne Jörns, Ortwin Naujok, Dirk Wedekind, Hans-Jürgen Hedrich, Sigurd Lenzen  Molecular Therapy  Volume 20, Issue 5, Pages 918-926 (May 2012) DOI: 10.1038/mt.2012.8 Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Reversal of a (a) mild and (b) severe diabetic metabolic state in STZ-diabetic rats through stable transduction of the liver by low titer INS-lentivirus injection. A stable mild diabetic state with blood glucose values in the range of 10 and 12 mmol/l was achieved through a single intravenous STZ injection (35 mg/kg b.wt.) five days before the lentiviral administration to hepatocytes by intraportal injection (day 0). Virus preparations were concentrated to a titer of 5 × 107/ml by ultrafiltration with Amicon Ultra columns. Stable persistent blood glucose normalization during a 1 year observation period was achieved after a single INS-lentivirus injection at day 0 within 5–10 days (closed circles). Administration of control EGFP-lentivirus did not cure diabetic rats (open circles). In comparable experiments with severely STZ-diabetic rats (55 mg/kg b.wt.) reduction of hyperglycemia with values above 20 mmol/l to stable persistent blood glucose values between 10 and 12 mmol/l for 1 year were achieved albeit glycemia was not fully normalized (closed circles). Blood glucose concentrations are presented as mean values ± SEM of six rats. The administration of INS-lentivirus resulted in human C-peptide concentrations of 49 ± 7 pmol/l for the mildly diabetic rats and 46 ± 9 pmol/l for the severely diabetic rats. In control rats treated with EGFP-lentivirus human C-peptide was not detectable. In mildly diabetic animals the rat C-peptide concentration was 54 ± 18 pmol/l. In severely diabetic animals rat C-peptide was below the detection limit. b.wt., body weight; EGFP, enhanced green fluorescent protein; STZ, streptozotocin. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Blood glucose and human C-peptide concentrations in STZ-diabetic rats transduced with a low dose of INS-lentivirus or control EGFP-lentivirus after an oral glucose tolerance test (OGTT) or a glibenclamide test. (a,b) An OGTT (2 g/kg b.wt.) was performed 60 days after injection of INS-lentivirus (closed circles) or 10 days after injection of EGFP-lentivirus (open circles) in severely STZ-diabetic (55 mg/kg b.wt.) and mildly STZ-diabetic (35 mg/kg b.wt.) rats. (c,d) Human serum C-peptide was measured in parallel in the animals. (e,f) Glibenclamide (0.5 mg/kg b.wt.) was injected intraperitoneally 30 days after injection of INS-lentivirus (closed circles) or 10 days after injection of EGFP-lentivirus (open circles) in mildly diabetic (35 mg/kg b.wt.) rats. Severely STZ-diabetic (in a, c, and e) rats and mildly STZ-diabetic rats (in b, d, and f) were treated with a low dose of INS-lentivirus 5 × 107 infectious particles. Values are presented as mean values ± SEM of 4–6 rats. b.wt., body weight; EGFP, enhanced green fluorescent protein; n.d., not detectable; STZ, streptozotocin. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Reversal of a severe diabetic metabolic state in STZ-diabetic rats through stable transduction of the liver by (a) high titer INS-lentivirus injection and (b) in comparison high titer mut-INS-lentivirus injection. A stable diabetic state was achieved through a single intravenous STZ injection (55 mg/kg b.wt.) 5 days before the lentiviral administration to hepatocytes by intraportal vein injection. Virus preparations were concentrated to a titer of 7 × 109/ml by tangential crossflow ultrafiltration. Persisting stable blood glucose normalization during a 1 year observation period was achieved after a single INS-lentivirus injection at day 0 within 5–7 days (closed circles). Administration of control EGFP-lentivirus did not cure diabetic rats (open circles). Blood glucose concentrations are presented as mean values ± SEM of six rats. The administration of INS-lentivirus or mut-INS-lentivirus resulted in human C-peptide concentrations of 101 ± 11 pmol/l and 101 ± 16 pmol, respectively. In control rats treated with EGFP-lentivirus human C-peptide was not detectable. The rat C-peptide concentration was in all groups of animals below the detection limit. b.wt., body weight; EGFP, enhanced green fluorescent protein; STZ, streptozotocin. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Reversal of a severe diabetic metabolic state in autoimmune-diabetic IDDM rats through stable transduction of the liver by high dose INS-lentivirus injection. Severely diabetic IDDM rats were treated 5–7 days after diabetes induction with an intraportal vein injection of lentivirus for the transduction of hepatocytes. Virus preparations were concentrated to titers of 7 × 109/ml by tangential crossflow ultrafiltration. Persisting stable blood glucose normalization during a 1 year observation period was achieved after a single INS-lentivirus injection at day 0 within 5–7 days (closed circles). Administration of control EGFP-lentivirus did not cure diabetic rats (open circles). Blood glucose concentrations are presented as mean values ± SEM of 4–6 rats. The administration of INS-lentivirus resulted in human C-peptide concentrations of 111 ± 11 pmol/l. In control rats treated with EGFP-lentivirus human C-peptide was not detectable. The rat C-peptide concentration was in both groups of animals below the detection limit. EGFP, enhanced green fluorescent protein. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Blood glucose concentrations in (a) severely STZ-diabetic rats or (b) autoimmune-diabetic IDDM rats transduced with a high dose INS-lentivirus or control EGFP-lentivirus after OGTT. An OGTT (2 g/kg b.wt.) was performed 60 days after injection of INS-lentivirus (closed circles) or 10 days after injection of EGFP-lentivirus (open circles) into diabetic rats. The virus dose in both groups of rats was 7 × 109 infectious particles per rat. Blood glucose concentrations are presented as mean values ± SEM of 4–6 rats. EGFP, enhanced green fluorescent protein; OGTT, oral glucose tolerance test; STZ, streptozotocin. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Immunofluorescence staining of liver tissue from IDDM rats transduced with (a,b) INS-lentivirus or (c,d) EGFP-lentivirus. Hepatocytes were positively stained either for insulin (a; red) or EGFP (c; green) in the specifically transduced cells and counterstained with DAPI (blue) in representative areas of paraffin sections. In control sections, in which EGFP-transduced liver tissue was stained for insulin, no immunofluorescence was detectable in d as well as in samples from INS-transduced liver tissue, which were stained for EGFP in b. DAPI, 4′,6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Ultrastructure of liver tissue from STZ-diabetic and IDDM rats transduced with (a) EGFP-lentivirus or (b,d) with INS-lentivirus in comparison to (c) no transduction. EGFP, enhanced green fluorescent protein; G, glycogen; M, mitochondria; STZ, streptozotocin. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 8 RT-PCR expression analyses of β-cell transcription factors in liver tissue of diabetic IDDM rats after transduction with INS- or EGFP-lentivirus. One year after transduction of diabetic IDDM rats with INS-lentivirus or 10 days after transduction of diabetic IDDM rats with EGFP-lentivirus RNA was isolated from liver tissue, reverse transcribed, and analyzed for expression of the following genes by PCR: pancreatic and duodenal homeobox 1 (Pdx1), neurogenic differentiation 1 (Neurod1), homeobox protein Nkx-6.1 (Nkx6-1), rat insulin 1 (rIns), human insulin (hIns), or enhanced green fluorescent protein (EGFP), β-actin (Actb). EGFP, enhanced green fluorescent protein; RT-PCR, reverse transcription-PCR. Molecular Therapy 2012 20, 918-926DOI: (10.1038/mt.2012.8) Copyright © 2012 The American Society of Gene & Cell Therapy Terms and Conditions